The Korean journal of internal medicine

  • 제27권4호
  • /
  • Pages.378-387
  • /
  • 2012
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Recent Paradigm Shifts in the Diagnosis and Treatment of Rheumatoid Arthritis

  • Jung, Young Ok (Department of Internal Medicine, Hallym University College of Medicine) ;
  • Kim, Hyun Ah (Department of Internal Medicine, Hallym University College of Medicine)
  • 발행 : 2012.12.01
⟨ 이전 논문 다음 논문 ⟩

초록

Rheumatoid arthritis (RA) is a progressive inflammatory disease with severe symptoms of pain and stiffness. Chronic persistent inflammation of RA often leads to joint destruction, deformity and limitation of function, which ultimately results in significant deterioration of quality of life (QoL). RA is characterized pathogenetically by immunologically driven, chronic synovitis, and production of autoantibodies, such as rheumatoid factor and anti-cyclic citrullinated peptide antibodies. Although the cause of RA is yet unknown, advances in the molecular biology led to in-depth understanding of its pathogenesis, and have fostered the recent development of novel treatments. The last decade has seen the dramatic change in the landscape of RA treatment with more aggressive therapy early in the disease course and with treatment guided by a structured assessment of disease activity, with the ultimate goal of reaching remission. In addition, prevention and control of joint damage and improvement in QoL are important goals. To achieve these goals, a multidisciplinary approach to reduce disease activity with disease modifying antirheumatic drugs and biological therapy is needed. We also need to find ways to identify those patients who are at risk for more rapid disease progression who would benefit from intensive therapy early in the course of disease.

키워드

참고문헌

  1. Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med 2010;25:1-17. https://doi.org/10.3904/kjim.2010.25.1.1
  2. Lee KH, Son MK, Ha YJ, et al. Inflammatory polyarthritis in a patient with psoriasis: is it psoriatic arthritis or rheumatoid arthritis? Korean J Intern Med 2010;25:224-226. https://doi.org/10.3904/kjim.2010.25.2.224
  3. Szekanecz Z, Pakozdi A, Szentpetery A, Besenyei T, Koch AE. Chemokines and angiogenesis in rheumatoid arthritis. Front Biosci (Elite Ed) 2009;1:44-51.
  4. Polzer K, Baeten D, Soleiman A, et al. Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints. Ann Rheum Dis 2008;67:1610-1616. https://doi.org/10.1136/ard.2007.083394
  5. Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998;161:409-414.
  6. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361:888-898. https://doi.org/10.1056/NEJMra0707449
  7. Chen Z, Laurence A, O'Shea JJ. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol 2007;19:400-408. https://doi.org/10.1016/j.smim.2007.10.015
  8. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007;204:33-39. https://doi.org/10.1084/jem.20061531
  9. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-1068. https://doi.org/10.1016/S0092-8674(05)80055-8
  10. Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:547-554.
  11. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581. https://doi.org/10.1056/NEJMoa032534
  12. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-310. https://doi.org/10.1016/S0092-8674(00)81109-5
  13. Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986;324:73-76. https://doi.org/10.1038/324073a0
  14. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-1276. https://doi.org/10.1172/JCI200420945
  15. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-1167. https://doi.org/10.1136/ard.2006.068064
  16. Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001;3:168-177. https://doi.org/10.1186/ar294
  17. Kirkham BW, Lassere MN, Edmonds JP, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006;54:1122-1131. https://doi.org/10.1002/art.21749
  18. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52ra72. https://doi.org/10.1126/scitranslmed.3001107
  19. Bradfield PF, Amft N, Vernon-Wilson E, et al. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 ($CXCL_{12}$), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. Arthritis Rheum 2003;48:2472-2482. https://doi.org/10.1002/art.11219
  20. Filer A, Parsonage G, Smith E, et al. Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: site-specific versus activation-dependent survival of T cells and neutrophils. Arthritis Rheum 2006;54:2096-2108. https://doi.org/10.1002/art.21930
  21. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-365. https://doi.org/10.1002/art.10117
  22. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152:943-951.
  23. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-2219. https://doi.org/10.1056/NEJMra1004965
  24. Simsek I. TNF inhibitors: new and old agents for rheumatoid arthritis. Bull NYU Hosp Jt Dis 2010;68:204-210.
  25. Ohta S, Tsuru T, Terao K, et al. Optimal dose prediction by pharmacokinetic and biomarker response of subcutaneous tocilizumab treatment: a phase I/II study evaluating the safety, pharmacokinetics and clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2010;62 Suppl 10:S1115.
  26. Guyot P, Taylor P, Christensen R, et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther 2011;13:R204. https://doi.org/10.1186/ar3537
  27. Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol 2011;23:245-251. https://doi.org/10.1097/BOR.0b013e3283454124
  28. Genovese MC, Durez P, Richards H, Hugot S, Thangavelu K, Mpofu S. Secukinumab (AIN457), a novel monoclonal antibody targeting IL-17A demonstrates efficacy in active rheumatoid arthritis patients despite stable methotrexate treatment: results of a phase IIb study [abstract]. Arthritis Rheum 2010;62:L9. https://doi.org/10.1002/art.25061
  29. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-1905. https://doi.org/10.1002/art.24567
  30. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH; Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011;63:1150-1158.
  31. Kremer J, Li ZG, Hall S, et al. Tofacitinib (CP-690,550), an oral JAK inhibitor, in combination with traditional DMARDs: phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs [abstract]. Ann Rheum Dis 2011;70(Suppl 3):170.
  32. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303-1312. https://doi.org/10.1056/NEJMoa1000500
  33. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324. https://doi.org/10.1002/art.1780310302
  34. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-1588. https://doi.org/10.1136/ard.2010.138461
  35. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-2581. https://doi.org/10.1002/art.27584
  36. Aggarwal R, Liao K, Nair R, Ringold S, Costenbader KH. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum 2009;61:1472-1483. https://doi.org/10.1002/art.24827
  37. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-637. https://doi.org/10.1136/ard.2009.123919
  38. Salomon-Escoto KI, Gravallese EM, Kay J. Assessment of control of rheumatoid arthritis disease activity. Best Pract Res Clin Rheumatol 2011;25:497-507. https://doi.org/10.1016/j.berh.2011.10.007
  39. Horton SC, Walsh CA, Emery P. Established rheumatoid arthritis: rationale for best practice: physicians' perspective of how to realise tight control in clinical practice. Best Pract Res Clin Rheumatol 2011;25:509-521. https://doi.org/10.1016/j.berh.2011.10.012
  40. Smolen JS, Aletaha D. Monitoring rheumatoid arthritis. Curr Opin Rheumatol 2011;23:252-258. https://doi.org/10.1097/BOR.0b013e328345743a
  41. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-740. https://doi.org/10.1002/art.1780360601
  42. van der Heijde DM, van 't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-920. https://doi.org/10.1136/ard.49.11.916
  43. Prevoo ML, van Gestel AM, van T Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996;35:1101-1105. https://doi.org/10.1093/rheumatology/35.11.1101
  44. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48. https://doi.org/10.1002/art.1780380107
  45. van Tuyl LH, Britsemmer K, Wells GA, et al. Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in the forefeet on outcome. Ann Rheum Dis 2012;71:33-37. https://doi.org/10.1136/ard.2011.153742
  46. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 Suppl 39):S100-S108.
  47. Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther 2011;13 Suppl 1:S3.
  48. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-346. https://doi.org/10.1002/art.10148
  49. Chen S, Gill MA, Luu CH, Takami S. Pain and rheumatoid arthritis: an update. Drug Topics 2000;3:47-56.
  50. Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 2006;45:1121-1124. https://doi.org/10.1093/rheumatology/kel054
  51. Kim HA, Seo YI, Jung YO, et al. The rate of attaining low disease activity with Methotrexate (MTX) based non-biological DMARD in patients with rheumatoid arthritis (RA): T-2-T data from 4 university affiliated Korean rheumatology clinics. J Rheum Dis 2012;19:S142.

피인용 문헌

  1. The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences vol.10, pp.8, 2012, https://doi.org/10.1586/1744666x.2014.926219
  2. Role of Endoplasmic Reticulum Stress in Rheumatoid Arthritis Pathogenesis vol.29, pp.1, 2014, https://doi.org/10.3346/jkms.2014.29.1.2
  3. Change of Psychological Distress and Physical Disability in Patients With Rheumatoid Arthritis Over the Last Two Decades : Two Decades of Psychological and Physical Health Improvement in RA vol.66, pp.5, 2012, https://doi.org/10.1002/acr.22211
  4. Identification of Potential Serum Biomarkers for Rheumatoid Arthritis by High-Resolution Quantitative Proteomic Analysis vol.37, pp.5, 2014, https://doi.org/10.1007/s10753-014-9871-8
  5. Role of C-reactive protein in osteoclastogenesis in rheumatoid arthritis vol.17, pp.None, 2012, https://doi.org/10.1186/s13075-015-0563-z
  6. Effectiveness of methotrexate therapy with occasional corticosteroid in rheumatoid arthritis vol.26, pp.2, 2012, https://doi.org/10.1097/bco.0000000000000213
  7. Compound K, a Metabolite of Ginsenosides, Attenuates Collagen-induced Arthritis in Mice vol.22, pp.3, 2012, https://doi.org/10.4078/jrd.2015.22.3.154
  8. Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits vol.65, pp.1, 2012, https://doi.org/10.1007/s12026-016-8824-8
  9. Methotrexate as effective and safe choice for the treatment of rheumatoid arthritis vol.28, pp.4, 2012, https://doi.org/10.1097/bco.0000000000000517
  10. Quality of life and functional capacity in patients with rheumatoid arthritis • Cross-sectional study vol.14, pp.6, 2018, https://doi.org/10.1016/j.reumae.2017.03.015